Patents : |  |
| US Patent No. | Title |
| 5869241 | Method of determining DNA sequence preference of a DNA-binding molecule
|
| 6468744 | Analysis of genetic polymorphisms and gene copy number
|
| 6469008 | (R)-hydroxynefazodone antipsychotic therapy
|
| 6528260 | Biallelic markers related to genes involved in drug metabolism
|
| 6534282 | Detection of hypertension using immunoreactive metabolic products
|
| 6586437 | (S)-hydroxynefazodone antipsychotic therapy
|
| 6643591 | Use of computational and experimental data to model organic compound reactivity in cytochrome P450 mediated reactions and to optimize the design of pharmaceuticals
|
| 6706731 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase
|
| 6727244 | Mammalian metabolites of a tachykinin receptor antagonist
|
| 6756229 | Human cell line showing stable expression of cytochromes P450
|
| 6768008 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
| 6440682 | Detection of hypertension using immunoreactive metabolic products
|
| 6433198 | Preparation of 6-.alpha.-hydroxy-7-deoxytaxanes using nocardioides luteus or a hydroxylase isolated therefrom
|
| 6420131 | Use of fluorescein aryl ethers in high throughput cytochrome P450 inhibition assays
|
| 5891633 | Defects in drug metabolism
|
| 5891696 | Compositions for cytochrome P450 biotransformation reactions
|
| 5912120 | Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
|
| 6010849 | Sequence-directed DNA binding molecules compositions and methods
|
| 6162622 | Preparation of 6 hydroxy-7-deoxytaxanes using nocardioides luteus
|
| 6200754 | Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
|
| 6207648 | Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
|
| 6287854 | Diagnosis of susceptibility to cancer and treatment thereof
|
| 6309823 | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
|
| 6384208 | Sequence directed DNA binding molecules compositions and methods
|
| 6784199 | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
|
| 6869765 | Sequence-directed DNA-binding molecules compositions and methods
|
| 7232663 | Assays employing novel substrates for measuring P450-mediated N-dealkylation
|
| 7265143 | C-4 substituted retinoids
|
| 7288243 | Aerosol drug inhibition of lung metastases
|
| 7307091 | Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
|
| 7312216 | N-phenyl-2-pyrimidine-amine derivatives
|
| 7323474 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase
|
| 7329661 | N-phenyl-3-pyrimidine-amine derivatives
|
| 7368242 | Method and kits for multiplex hybridization assays
|
| 7378434 | Metaxalone products, method of manufacture, and method of use
|
| 7399761 | Phthalazine derivatives with angiogenesis inhibiting activity
|
| 7226742 | Method for detecting base mutation
|
| 7186553 | Human derived immortalized liver cell line
|
| 7183289 | 39-desmethoxyrapamycin, compositions and methods of use thereof
|
| 6958355 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
| 7015008 | Antibodies for human cytochrome P450 2D6
|
| 7056654 | Screening assay for inhibitors of human cytochrome P-450
|
| 7081340 | Gene expression profiling in biopsied tumor tissues
|
| 7081532 | N-phenyl-2-pyrimidine-amine derivatives
|
| 7090868 | Materials and methods for drug delivery and uptake
|
| 7107155 | Methods for the identification of genetic features for complex genetics classifiers
|
| 7122566 | Metaxalone products, method of manufacture, and method of use
|
| 7153652 | Mismatch repair detection
|
| 7183105 | Eubacterial minicells and their use as vectors for nucleic acid delivery and expression
|
| 7407772 | Screening and selection methods for statin drug combinations
|
